GlassScriptPhysician profile
Maurice Mosseri
NPI 1033730387
$392.51
in general payments reported to CMS, 2019-2025
15 companies · $393 in 2025
The $393 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.64 | 2025 | |
| Rgh Enterprises LLC | $50.73 | 2025 | |
| Insulet Corporation | $48.05 | 2025 | Omnipod |
| Lilly USA, LLC | $35.22 | 2025 | Mounjaro |
| Amgen INC. | $31.94 | 2025 | Tepezza |
| Sequel Med Tech, LLC | $25.99 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $20.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.04 | 2025 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $17.92 | 2025 | |
| Beta Bionics, INC. | $17.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Chiesi USA, INC. | $15.81 | 2025 | Mycapssa |
| Madrigal Pharmaceuticals | $14.94 | 2025 | Rezdiffra |
| Corcept Therapeutics | $14.61 | 2025 | Korlym |
| Abbvie INC. | $14.51 | 2025 | |
| Tandem Diabetes Care, INC. | $14.20 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Mosseri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.